Form 4: SeaStar Medical CEO Awarded 65,000 Restricted Stock Units

SeaStar Medical's CEO, Eric Schlorff, was granted 65,000 restricted stock units (RSUs) that vest over three years.

Summary

• Eric Schlorff, the CEO of SeaStar Medical Holding Corporation, was granted 65,000 restricted stock units (RSUs) on November 15, 2024.
• These RSUs represent a contingent right to receive one share of SeaStar Medical's common stock per unit.
• The RSUs will vest in equal installments on the first, second, and third anniversaries of July 1, 2024.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of RSUs to the CEO aligns his interests with the long-term performance of the company.
• The vesting schedule encourages the CEO's continued commitment to the company over the next three years.

Risks

• The vesting of the RSUs is contingent on the CEO's continued employment with the company.

Future Outlook

The vesting of the RSUs is tied to the CEO's continued service over the next three years.

Industry Context

The granting of stock-based compensation is a common practice for incentivizing executives in publicly traded companies, particularly in the biotech and medical device sectors.

Comparison to Industry Standards

• Stock-based compensation is a standard practice in the industry, with companies like Medtronic and Boston Scientific also using similar methods to incentivize their executives.
• The vesting schedule of three years is also typical for RSU grants in the industry, aligning with long-term performance goals.

Stakeholder Impact

• The grant of RSUs to the CEO is intended to align his interests with those of the shareholders, encouraging long-term value creation.

Key Dates

Keywords

restricted stock units, RSU, executive compensation, SeaStar Medical, Eric Schlorff, stock options, equity